Vanzacaftor
Vanzacaftor is a next-generation CFTR corrector being developed in combination therapy for the treatment of cystic fibrosis.
Detailed technical, regulatory, and supply information is available for commercial evaluation.
Technical Overview
Vanzacaftor – CAS 2374124-49-7
CAS Number
2374124-49-7
Category
Cystic fibrosis
Therapeutic Class
CFTR corrector
Description
Vanzacaftor is a next-generation CFTR corrector being developed in combination therapy for the treatment of cystic fibrosis.
Applications
- Cystic fibrosis
Handling & Supply Details
Packaging
Standard export packaging in double-lined HDPE drums or fiber drums with inner poly liners; custom pack sizes available on request.
Product Inquiry
Disclaimer
Products offered are intended strictly for R&D, registration and/or export purposes only. The responsibility for ensuring that the product does not infringe any third-party patent or intellectual property rights in the destination country rests solely with the buyer.